First Heartland Consultants’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-8,589
| Closed | -$211K | – | 472 |
|
|
2024
Q3 | $211K | Buy |
+8,589
| New | +$211K | 0.02% | 427 |
|
|
2024
Q2 | – | Sell |
-8,553
| Closed | -$206K | – | 452 |
|
|
2024
Q1 | $206K | Buy |
+8,553
| New | +$206K | 0.02% | 405 |
|
|
2023
Q1 | – | Sell |
-8,472
| Closed | -$213K | – | 371 |
|
|
2022
Q4 | $213K | Hold |
8,472
| – | – | 0.03% | 347 |
|
|
2022
Q3 | $223 | Hold |
8,472
| – | – | 0.02% | 314 |
|
|
2022
Q2 | $244K | Sell |
8,472
-458
| -5% | -$13.2K | 0.04% | 293 |
|
|
2022
Q1 | $307K | Sell |
8,930
-100
| -1% | -$3.44K | 0.05% | 260 |
|
|
2021
Q4 | $395 | Buy |
9,030
+51
| +0.6% | +$2 | 0.02% | 232 |
|
|
2021
Q3 | $455K | Buy |
8,979
+100
| +1% | +$5.07K | 0.07% | 212 |
|
|
2021
Q2 | $462K | Sell |
8,879
-7
| -0.1% | -$364 | 0.07% | 222 |
|
|
2021
Q1 | $406K | Buy |
8,886
+2,926
| +49% | +$134K | 0.06% | 237 |
|
|
2020
Q4 | $274K | Buy |
+5,960
| New | +$274K | 0.05% | 257 |
|